Many experts are frustrated and troubled by the state of HER2 testing, especially as new opportunities for tests are on the horizon. And as trials testing Herceptin at earlier stages and in ...

It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer involves tumor cells that test positive for hormone receptors and negative for HER2 proteins. Cancer cells with estrogen ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

The Ventana HER2 test can be used to identify patients with low human epidermal growth factor receptor 2 (HER2) expression, who can best benefit from Enhertu. "Caris Life Sciences nabs FDA ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

A recent study compared HER2-low breast cancer with HER2-negative breast cancer and found lower immune response with HER2-low cancer, which could hold possible therapeutic implications in the future.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

When treating patients with hormone-receptor positive, HER2-negative metastatic breast cancer, mutations necessitate the ...